Facebook
Linkedin
RSS
Twitter
Homepage
How To Invest
News
Economy
Small Business
Technology
Personal Finance
Press Releases
Consumer Goods
Consumer Services
Energy
Finance
Health Care
Industrials
Materials
Mining
Real Estate
Technology
Telecommunications
Utilities
Retirement
Stock Trading Strategies
Search
Search
22.6
C
New York
Saturday, June 13, 2026
Homepage
How To Invest
News
Economy
Small Business
Technology
Personal Finance
Press Releases
Consumer Goods
Consumer Services
Energy
Finance
Health Care
Industrials
Materials
Mining
Real Estate
Technology
Telecommunications
Utilities
Retirement
Stock Trading Strategies
KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026
FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know
Search
22.6
C
New York
Saturday, June 13, 2026
Homepage
How To Invest
News
Economy
Small Business
Technology
Personal Finance
Press Releases
Consumer Goods
Consumer Services
Energy
Finance
Health Care
Industrials
Materials
Mining
Real Estate
Technology
Telecommunications
Utilities
Retirement
Stock Trading Strategies
Tag:
Duality Biotherapeutics
news
source
FOR
company
information
content
1
market
releases
DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today...
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today...
- A word from our sponsors -
Newsletter Signup
Name
(Required)
First
Last
Company Name
Email
(Required)
Enter Email
Confirm Email
CAPTCHA
Privacy
(Required)
I agree with the storage and handling of my data by this website. -
Privacy Policy
*
Phone
This field is for validation purposes and should be left unchanged.
Home
Tags
Duality Biotherapeutics